{"quoteSummary":{"result":[{"defaultKeyStatistics":{"maxAge":1,"priceHint":{"raw":2,"fmt":"2","longFmt":"2"},"enterpriseValue":{"raw":1018543424,"fmt":"1.02B","longFmt":"1,018,543,424"},"forwardPE":{},"profitMargins":{"raw":0.056999996,"fmt":"5.70%"},"floatShares":{"raw":465932254,"fmt":"465.93M","longFmt":"465,932,254"},"sharesOutstanding":{"raw":780652032,"fmt":"780.65M","longFmt":"780,652,032"},"sharesShort":{},"sharesShortPriorMonth":{},"heldPercentInsiders":{},"heldPercentInstitutions":{},"shortRatio":{},"shortPercentOfFloat":{},"beta":{"raw":-1.211959,"fmt":"-1.21"},"morningStarOverallRating":{},"morningStarRiskRating":{},"category":null,"bookValue":{"raw":1.503,"fmt":"1.50"},"priceToBook":{"raw":3.127079,"fmt":"3.13"},"annualReportExpenseRatio":{},"ytdReturn":{},"beta3Year":{},"totalAssets":{},"yield":{},"fundFamily":null,"fundInceptionDate":{},"legalType":null,"threeYearAverageReturn":{},"fiveYearAverageReturn":{},"priceToSalesTrailing12Months":{},"lastFiscalYearEnd":{"raw":1490918400,"fmt":"2017-03-31"},"nextFiscalYearEnd":{"raw":1553990400,"fmt":"2019-03-31"},"mostRecentQuarter":{"raw":1396224000,"fmt":"2014-03-31"},"earningsQuarterlyGrowth":{"raw":1.426,"fmt":"142.60%"},"revenueQuarterlyGrowth":{},"netIncomeToCommon":{"raw":105341008,"fmt":"105.34M","longFmt":"105,341,008"},"trailingEps":{"raw":0.135,"fmt":"0.14"},"forwardEps":{},"pegRatio":{},"lastSplitFactor":"7/2","lastSplitDate":{"raw":1376870400,"fmt":"2013-08-19"},"enterpriseToRevenue":{"raw":0.551,"fmt":"0.55"},"enterpriseToEbitda":{"raw":6.183,"fmt":"6.18"},"52WeekChange":{"raw":1.4892473,"fmt":"148.92%"},"SandP52WeekChange":{"raw":0.12668931,"fmt":"12.67%"},"lastDividendValue":{},"lastCapGain":{},"annualHoldingsTurnover":{}},"summaryProfile":{"address1":"Tagore Centre, Dawa Bazar","address2":"2nd Floor 13-14, R.N.T. Marg GPO PB No. 610","city":"Indore","zip":"452001","country":"India","phone":"91 73 1304 6868","fax":"91 73 1304 6870","website":"http://www.syncomformulations.com","industry":"Drug Manufacturers - Major","sector":"Healthcare","longBusinessSummary":"Syncom Formulations (India) Limited, a pharmaceutical company, discovers, develops, manufactures, and markets a range of healthcare products in India. The company offers approximately 500 pharmaceutical formulations in various dosage forms, such as tablets, capsules, liquids, liquid ampoules and dry vial injections, dry syrups, ointments, inhalers, and herbals. Its products comprise generics, alpha adrenoceptor agonists, analgesics, antipyretics, anti-inflammatory, anti-ulcer agents, antibiotics, antidepressants, antifungals, antihistamines, antimalarial, antiplatelet agents, antiprotozoal, antivirals, bronchodilators, calcium antagonists, cardiac medicines, central nervous stimulants, cephelo sporins, cortico steroids, estrogen, cough suppressants, erectile dysfunction, and electrolite. The company also offers histamines, homeostatic, hypoglycemic, hypolipidaemics, local anesthetics, multivitamins and nutritional supplements, sedative anticonvulsants, stimulants, and sympathomimetic products, as well as products used in the treatment of gout. In addition, it exports active pharmaceutical ingredients and surgical products; agro and confectionary products comprising rice, wheat flour, chickpeas, soy doc, biscuits, and candies; and fasteners, steel bars, roofing sheets, and jute bags, as well as metal scrap. Additionally, the company rents properties. Syncom Formulations (India) Limited was founded in 1985 and is based in Indore, India.","fullTimeEmployees":927,"companyOfficers":[],"maxAge":86400},"financialData":{"maxAge":86400,"currentPrice":{"raw":4.7,"fmt":"4.70"},"targetHighPrice":{},"targetLowPrice":{},"targetMeanPrice":{},"targetMedianPrice":{},"recommendationMean":{},"recommendationKey":"none","numberOfAnalystOpinions":{},"totalCash":{"raw":52760000,"fmt":"52.76M","longFmt":"52,760,000"},"totalCashPerShare":{"raw":0.068,"fmt":"0.07"},"ebitda":{"raw":164728032,"fmt":"164.73M","longFmt":"164,728,032"},"totalDebt":{"raw":33036000,"fmt":"33.04M","longFmt":"33,036,000"},"quickRatio":{"raw":1.141,"fmt":"1.14"},"currentRatio":{"raw":1.503,"fmt":"1.50"},"totalRevenue":{"raw":1848224256,"fmt":"1.85B","longFmt":"1,848,224,256"},"debtToEquity":{"raw":3.47,"fmt":"3.47"},"revenuePerShare":{"raw":2.368,"fmt":"2.37"},"returnOnAssets":{"raw":0.047030002,"fmt":"4.70%"},"returnOnEquity":{"raw":0.0932,"fmt":"9.32%"},"grossProfits":{"raw":560007930,"fmt":"560.01M","longFmt":"560,007,930"},"freeCashflow":{"raw":-93234024,"fmt":"-93.23M","longFmt":"-93,234,024"},"operatingCashflow":{"raw":138408992,"fmt":"138.41M","longFmt":"138,408,992"},"earningsGrowth":{"raw":1.19,"fmt":"119.00%"},"revenueGrowth":{"raw":0.234,"fmt":"23.40%"},"grossMargins":{"raw":0.303,"fmt":"30.30%"},"ebitdaMargins":{"raw":0.08913,"fmt":"8.91%"},"operatingMargins":{"raw":0.07238,"fmt":"7.24%"},"profitMargins":{"raw":0.056999996,"fmt":"5.70%"},"financialCurrency":"INR"}}],"error":null}}